NCT01352182View on ClinicalTrials.gov

Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

May 31, 2016

Study Completion Date

January 31, 2017

Conditions
Severe SepsisSeptic Shock
Interventions
DRUG

Pioglitazone hydrochloride

Participants will receive a daily dose of pioglitazone at 0.5 mg/kg/dose for 5 days.

Trial Locations (1)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT01352182 - Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock | Biotech Hunter | Biotech Hunter